Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Severe Pneumonia, Community-acquired Pneumonia, Hospital-acquired Pneumonia
About this trial
This is an interventional treatment trial for Severe Pneumonia focused on measuring mechanical ventilation, severe pneumonia, critical illness, CPIS, Ambroxol
Eligibility Criteria
Inclusion Criteria: Patients aged > 18 years old Mechanically ventilated due to severe community or hospital acquired pneumonia Exclusion Criteria: Patients aged <18 years old Pregnant and lactating patients Patients with known allergies to ambroxol hydrochloride Patients with aspartate aminotransferase (AST) >5 times the upper limit of normal at the time of recruitment Moribund patients who are expected to not survive within 24 hours of ICU admission
Sites / Locations
- Hospital Canselor Tuanku Muhriz UKM (HCTM)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Ambroxol Arm
Control Arm
Amboxol arm will be receiving "standard therapy" as per control group with the addition of IV ambroxol hydrochloride 30mg TDS as adjunct therapy for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour. The patients will be considered as drop-outs if ambroxol is discontinued due to its side-effects, or if the patient's duration of ICU stay is less than 24 hours.
Control arm will be receiving "standard therapy" for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC).37 This includes antibiotics stewardship and supportive therapy.